EMA Authorised: Ofev (nintedanib) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The European Medicines Agency authorised a label expansion for Ofev (nintedanib) to cover additional interstitial lung diseases, including systemic sclerosis-as…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Pulmonary Fibrosis
• Systemic Sclerosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• OFEV (Nintedanib)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis;Lung Diseases, Interstitial;Pulmonary Fibrosis;Scleroderma, Systemic. MAH: Boehringer Ingelheim International GmbH. Decision date: 05/01/2026. Accelerated assessment